Annika Laukkanen1, Linda Emaus, Ville Pettilä, Kirsi-Maija Kaukonen. 1. Intensive Care Unit, Division of Anaesthesiology and Intensive Care Medicine, Department of Surgery, Helsinki University Central Hospital, PO Box 340, 00029 HUS Helsinki, Finland. annika.laukkanen@hus.fi
Abstract
PURPOSE: Assessment of the cost utility (CU) of acute renal replacement therapy (RRT) from a societal perspective during a 5-year follow-up. METHODS: This was a cross-sectional cohort study in a medical-surgical intensive care unit and an acute RRT unit of 410 consecutive patients treated with acute RRT in Helsinki University Hospital in 2000-2002. Five-year survival and health-related quality of life (HRQoL) were assessed and used to calculate quality-adjusted life years (QALYs) in two ways. They were first calculated for the 5-year follow-up period and, second, estimated for the expected lifetime. HRQoL was assessed by the EuroQol (EQ-5D) in 2003. The cost analysis included hospital costs during index hospitalization along with hospital and societal costs for the following 5 years. The CU ratio was determined as total costs divided by gained QALYs. RESULTS: Median survival time for all patients was 0.20 years and the EQ-5D index score was 0.68, 0.18 lower than that of the age- and gender-matched general population. All RRT-treated patients gained 0.10 QALYs/patient and hospital survivors 2.54 QALYs in 5 years. Overall the CU ratio was poor [5 year median 271,116 (29,782-2,177,581) €/QALY]. However, it was acceptable (less than 50,000 €/QALY) in patients who survived for more than a year and did not need chronic RRT. Cost utility decreased with increasing age exceeding 1.0 million €QALY in the older groups. CONCLUSIONS: In general, the CU ratio of acute RRT is poor. However, it is acceptable in patients with renal recovery who survive for more than 1 year.
PURPOSE: Assessment of the cost utility (CU) of acute renal replacement therapy (RRT) from a societal perspective during a 5-year follow-up. METHODS: This was a cross-sectional cohort study in a medical-surgical intensive care unit and an acute RRT unit of 410 consecutive patients treated with acute RRT in Helsinki University Hospital in 2000-2002. Five-year survival and health-related quality of life (HRQoL) were assessed and used to calculate quality-adjusted life years (QALYs) in two ways. They were first calculated for the 5-year follow-up period and, second, estimated for the expected lifetime. HRQoL was assessed by the EuroQol (EQ-5D) in 2003. The cost analysis included hospital costs during index hospitalization along with hospital and societal costs for the following 5 years. The CU ratio was determined as total costs divided by gained QALYs. RESULTS: Median survival time for all patients was 0.20 years and the EQ-5D index score was 0.68, 0.18 lower than that of the age- and gender-matched general population. All RRT-treated patients gained 0.10 QALYs/patient and hospital survivors 2.54 QALYs in 5 years. Overall the CU ratio was poor [5 year median 271,116 (29,782-2,177,581) €/QALY]. However, it was acceptable (less than 50,000 €/QALY) in patients who survived for more than a year and did not need chronic RRT. Cost utility decreased with increasing age exceeding 1.0 million €QALY in the older groups. CONCLUSIONS: In general, the CU ratio of acute RRT is poor. However, it is acceptable in patients with renal recovery who survive for more than 1 year.
Authors: Annika Ahlström; Anne Kuitunen; Seija Peltonen; Marja Hynninen; Minna Tallgren; Janne Aaltonen; Ville Pettilä Journal: Am J Kidney Dis Date: 2006-08 Impact factor: 8.860
Authors: B Delannoy; B Floccard; F Thiolliere; M Kaaki; M Badet; S Rosselli; C E Ber; A Saez; G Flandreau; Claude Guérin Journal: Intensive Care Med Date: 2009-08-20 Impact factor: 17.440
Authors: Amar A Desai; Jacqueline Baras; Benjamin B Berk; Aya Nakajima; Alan M Garber; Douglas Owens; Glenn M Chertow Journal: Arch Intern Med Date: 2008-09-08
Authors: Sean M Bagshaw; Kevin B Laupland; Christopher J Doig; Garth Mortis; Gordon H Fick; Melissa Mucenski; Tomas Godinez-Luna; Lawrence W Svenson; Tom Rosenal Journal: Crit Care Date: 2005-10-25 Impact factor: 9.097
Authors: Giuseppe Citerio; Jan Bakker; Matteo Bassetti; Dominique Benoit; Maurizio Cecconi; J Randall Curtis; Glenn Hernandez; Margaret Herridge; Samir Jaber; Michael Joannidis; Laurent Papazian; Mark Peters; Pierre Singer; Martin Smith; Marcio Soares; Antoni Torres; Antoine Vieillard-Baron; Jean-François Timsit; Elie Azoulay Journal: Intensive Care Med Date: 2013-12-13 Impact factor: 17.440
Authors: Meri Poukkanen; Suvi T Vaara; Matti Reinikainen; Tuomas Selander; Sara Nisula; Sari Karlsson; Ilkka Parviainen; Juha Koskenkari; Ville Pettilä Journal: Crit Care Date: 2015-03-27 Impact factor: 9.097
Authors: Rahul Raj; Stepani Bendel; Matti Reinikainen; Sanna Hoppu; Teemu Luoto; Tero Ala-Kokko; Sami Tetri; Ruut Laitio; Timo Koivisto; Jaakko Rinne; Riku Kivisaari; Jari Siironen; Alisa Higgins; Markus B Skrifvars Journal: Crit Care Med Date: 2018-04 Impact factor: 7.598
Authors: Robert Faulhaber-Walter; Sebastian Scholz; Herrmann Haller; Jan T Kielstein; Carsten Hafer Journal: Int J Nephrol Renovasc Dis Date: 2016-05-23